2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

Dades bibliogràfiques
Format:	Article
Idioma:	English
Publicat:	Korean Association for the Study of the Liver 2018-09-01
Col·lecció:	Clinical and Molecular Hepatology
Matèries:	Chronic hepatitis C Treatment Direct acting antivirals Guidelines
Accés en línia:	http://e-cmh.org/upload/pdf/cmh-2018-1004.pdf

Ítems similars

KASL clinical practice guidelines: Management of Hepatitis C
Publicat: (2014-06-01)

KASL clinical practice guidelines for management of chronic hepatitis B
Publicat: (2019-06-01)

KASL clinical practice guidelines for management of chronic hepatitis B
Publicat: (2022-04-01)

KASL Clinical Practice Guidelines: Management of chronic hepatitis B
Publicat: (2012-06-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
per: Özlem KANDEMİR
Publicat: (2018-12-01)

Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL
per: Jong Eun Yeon
Publicat: (2018-09-01)

KASL clinical practice guidelines for management of autoimmune hepatitis 2022
Publicat: (2023-07-01)

New drugs in the treatment of chronic hepatitis C
per: R. Jimenez Galan, et al.
Publicat: (2014-04-01)

Current Treatment Of Chronıc Hepatıtıs C Genotype 1
per: Mesut Aydın, et al.
Publicat: (2018-10-01)

Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? – Indications for Treatment
per: Kyung-Ah Kim
Publicat: (2016-03-01)

Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
per: Chung-Feng Huang, et al.
Publicat: (2020-07-01)

2018 Korean Association for the Study of the Liver (KASL) Clinical Practice Guidelines of Chronic Hepatitis B: What’s Different?
per: Ji Hoon Kim
Publicat: (2019-03-01)

Hepatitis C Treatment: A Review and Update
per: Jelena Jakab, et al.
Publicat: (2017-04-01)

Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
per: Yuri Cho, et al.
Publicat: (2015-12-01)

Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals
per: Soon Young Ko, et al.
Publicat: (2018-12-01)

Hepatitis C Virus Infection in Europe
per: Margarida Simão, et al.
Publicat: (2024-09-01)

A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C
per: Jessica Ramsay, et al.
Publicat: (2020-10-01)

NOVEL DIRECT ACTING ANTIVIRAL REGIMENS FOR PATIENTS WITH CHRONIC HEPATITIS C AND CHRONIC KIDNEY DISEASE STAGE 3 TO STAGE 5D
per: Nauman Kashif, et al.
Publicat: (2020-08-01)

Sofosbuvir and Ribavirin in Chronic Hepatitis C Virus Patients with No Response or Relapse with Interferon Therapy
per: Shaimuna Fareeha Sajjad, et al.
Publicat: (2020-12-01)

High efficacy and safety of direct‐acting antivirals for the treatment of chronic hepatitis C: A cohort study conducted in Vietnam
per: Thong Duy Vo, et al.
Publicat: (2024-10-01)

New treatment of hepatitis C (Direct Acting Antiviral)
per: Mohsen Akhondi-Meybodi
Publicat: (2019-10-01)

Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017
per: Christer F. Aas, et al.
Publicat: (2020-06-01)

Planning a clinical trial programme for direct-acting antivirals for chronic viral hepatitis C
per: A. I. Gubenko, et al.
Publicat: (2023-12-01)

Antiviral therapy in chronic hepatitis C virus infection
per: Irina Russu
Publicat: (2019-09-01)

Direct-Acting Antiviral Agents for Hepatitis C Virus Infection—From Drug Discovery to Successful Implementation in Clinical Practice
per: Christopher Dietz, et al.
Publicat: (2022-06-01)

Are There Still Difficult-to-Treat Patients with Chronic Hepatitis C in the Era of Direct-Acting Antivirals?
per: Paweł Pabjan, et al.
Publicat: (2022-01-01)

Problematic issues of the effectiveness of treatment of patients with chronic viral hepatitis C according to the State program and the ways of their solution.
per: L. R. Shostakovych-Koretska, et al.
Publicat: (2018-11-01)

Hepatitis C treatment: where are we now?
per: Burstow NJ, et al.
Publicat: (2017-02-01)

Cost-effectiveness of treating hepatitis C in Seychelles
per: Naomi Joan Faray Adeline, et al.
Publicat: (2019-05-01)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
per: Cassia Leal, et al.
Publicat: (2023-01-01)

Adolescents with chronic hepatitis C might be good candidates for direct‐acting antiviral therapy
per: Ken Sato, et al.
Publicat: (2022-04-01)

Impact of direct-acting antivirals on neuropsychiatric and neurocognitive dysfunction in chronic hepatitis C patients
per: Ghaydaa A. Shehata, et al.
Publicat: (2022-12-01)

Emerging Therapies for Hepatitis C
Publicat: (2014-09-01)

Chronic hepatitis C virus infection: An internist’s opinion (Part 1)
per: M L Zubkin, et al.
Publicat: (2016-10-01)

Hepatitis C in Children—An Asia–Pacific Concise Perspective
per: Lynette Goh, et al.
Publicat: (2024-10-01)

The impact of direct-acting antivirals on quality of life in patients with hepatitis C virus infection: a meta-analysis
per: Na He, et al.
Publicat: (2022-07-01)

Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021
per: Xinyu Du, et al.
Publicat: (2023-03-01)

Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study
per: Heidar Sharafi, et al.
Publicat: (2020-01-01)

Distribution of Primary Resistance Mutations in Saint Petersburg in Patients with Chronic Hepatitis C
per: Diana Valutite, et al.
Publicat: (2022-04-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
per: Byung Soo Kwan, et al.
Publicat: (2021-03-01)